Relmada Therapeutics Inc. stocks have been trading up by 12.28 percent amid heightened optimism over its latest clinical trial progress.
Click Here for a Millionaire's POV on Trading RLMD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Shares climbed nearly 11% after the CEO and CFO each bought 200,000 shares, with volume holding near the daily average.
- A recent Form 4 filing confirmed changes in insider or major shareholder ownership, highlighting active insider positioning.
- Upcoming one-on-one meetings at the Wells Fargo healthcare conference will spotlight the company’s oncology and CNS pipeline.
- Price pushed from the low $4s toward the mid-$4s, showing fresh momentum after the insider buying.
Weekly Update Sep 07 – Sep 11, 2026: On Sunday, September 13, 2026 Relmada Therapeutics Inc. stock [NASDAQ: RLMD] is trending up by 12.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Relmada Therapeutics is a micro-cap, clinical‑stage biotech with no product revenue and deeply negative profitability (ROE ~‑56%, ROA ~‑52%), typical of precommercial CNS/oncology peers. Cash of ~$218M in cash and short-term investments, zero debt, and an extremely high current ratio (~29.5x) provide a multiyear runway despite quarterly operating cash burn of ~$9.6M. Book value per share of $1.94 and price‑to‑book of 2.3x are reasonable given pipeline optionality and small 17‑employee footprint.
Weekly trading data show RLMD breaking sharply higher from the $4.07–4.10 area to close near $4.57, signaling a short‑term bullish reversal and likely short‑covering. Intraday 5‑minute candles (not shown here, but consistent with the weekly range expansion) indicate strong demand on upticks with volume accelerating on green bars. The key actionable level is support at $4.10: above this, bias is long with near‑term upside toward $5.00; a decisive break below $4.10 invalidates the trade.
More Breaking News
- NCPL Stock Volatility Draws Day Traders After Sudden Spike
- IFBD Stock Whipsaws As Traders Target Low-Float Volatility
- SRFM Stock Climbs As SurfOS Wins New Airline Deals
- MXL Stock Climbs As Traders Eye Benchmark Meeting
Recent insider buying by the CEO and CFO (200,000 shares each) is a strong positive signal in small‑cap biotech, validating management’s confidence ahead of upcoming conference visibility at Wells Fargo’s healthcare event. Versus broader Healthcare and Biotechnology benchmarks, RLMD remains higher risk but has a cleaner balance sheet and higher insider alignment. Near term, I expect continued speculative accumulation; key support sits at $4.10, resistance at $5.25. My 6‑12 month risk‑tolerant upside target is $6.00.
Quick Financial Overview
Relmada Therapeutics Inc. (RLMD) has just seen a sharp sentiment shift, with an almost 11% price pop tied to sizable insider buying by the CEO and CFO. On the short-term chart, weekly action shows the stock trading around the low $4 area early in the week, then spiking to a high near $4.61 and closing around $4.57. That move off the $4.07–$4.10 zone signals a clear push from recent support toward new near-term resistance.
Intraday, a 5-minute candle shows RLMD trading in a wide range between roughly $4.30 and $4.65 before settling close to $4.52. That kind of intraday range, with a strong close, tells traders that buyers were willing to step in on dips and absorb supply. With volume reported near the daily average during the 11% surge, this was not a one-off low-liquidity spike; it reflects real money rotating in, even if liquidity is still modest.
Financially, Relmada Therapeutics Inc. is a high-risk clinical-stage name with negative earnings and no clear revenue contribution in the ratios data. The latest quarterly report shows a net loss of about $12.9M, or roughly -$0.11 per share, and operating cash flow around -$9.6M. At the same time, the balance sheet carries roughly $217.7M in cash and short-term investments, a current ratio near 29.5, and no long-term debt, giving RLMD meaningful cash runway for its oncology and CNS programs.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.